Drug Profile
Research programme: VP 600 series - Virium Pharmaceuticals
Alternative Names: VP 601; VP600 series - Virium PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Medicine & Dentistry of New Jersey
- Developer Virium Pharmaceuticals
- Class Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 23 Apr 2008 Preclinical trials in Cancer in USA (PO)